Our objective was to examine the association between myocardial infarction (MI) and two DNA-polymorphisms at the proinflammatory chemokine receptors CCR2 (I64V) and CCR5 (32 bp deletion, ⌬ccr5), defining if these polymorphisms influence the age for the onset of MI. A total of 214 patients with an age at the first MI episode Ͻ55 years, 96 patients that suffered the first MI episode when older than 60 years, and 360 population controls were polymerase chain reaction genotyped for the CCR2-V64I and CCR5-⌬32/wt polymorphisms. Patients and controls were male from the same Caucasian population (Asturias, northern Spain). The frequency of the ⌬ccr5 allele was significantly higher in controls compared to patients Ͻ55 years (P = 0.004), or in patients Ͼ60 years compared to patients Ͻ55 years (P = 0.002). Taking the patients Ͼ60 years as the reference group, non-carriers of the ⌬ccr5-allele would have a three-fold higher risk of suffering an episode of MI at Ͻ55 years of age (OR = 3.06; 95% CI = 1.46-6.42). Gene and genotype frequencies for the CCR2 polymorphism did not differ between patients Ͻ55 years and controls or patients Ͼ60 years. Our data suggest that the variation at the CCR5 gene could modulate the age at the onset of MI. Patients carrying the ⌬ccr5-allele would be protected against an early episode of MI. CCR5 and the CCR5-ligands are expressed by cells in the arteriosclerotic plaque. Thus, the protective role of ⌬ccr5 could be a consequence of an attenuated inflammatory response, that would determine a slower progression of the arteriosclerotic lesion among ⌬ccr5-carriers. Our work suggests that the pharmacological blockade of CCR5 could be a valuable therapy in the treatment of MI. Genes and Immunity (2001) 2, 191-195. 
Introduction
The immune inflammatory response is involved in the development of the arteriosclerotic lesion. 1, 2 Chemokines are proinflammatory cytokines that recruit leukocytes from the blood into tissues, thus playing a pivotal role in human inflammatory diseases. 3, 4 Among these chemokines, MCP-1 (monocyte chemoattractant protein-1), RANTES (regulated on activation, normal T cell expressed and secreted), and the macrophage inflammatory proteins-1 (MIP-1) alpha and beta act on lymphocytes, eosinophils, monocyte/macrophages, and basophils, and have been detected in arteriosclerotic plaques. [5] [6] [7] [8] MCP-1 is expressed by stimulated cultured vascular smooth muscle cells. 9, 10 In addition, MCP-1 is upregulated in arteries of primates on a hypercholesterolaemic diet, and there is a growing evidence that the lipid-ladden macrophages (foam cells) that characterise the fatty streak arteriosclerotic lesions could be recruited to the vessel wall by these chemokines. 11, 12 Chemokines exert their biological functions through binding to seven-transmembrane G-protein coupled receptors. Two of these, CCR2 and CCR5, bind MCP-1 (CCR2) and RANTES, MIP-1alpha or MIP-1beta (CCR5). 4, 13 As part of the proinflammatory response, these receptors could be involved in the initiation and progression of arteriosclerosis. CCR2 and CCR5 have recently been identified on vascular smooth muscle cells, where they may influence proliferation and migration. 14, 15 Apolipoprotein E (ApoE) null mice develop severe atherosclerosis, and these ApoE-null mice also lacking CCR2 showed a decreased arteriosclerotic lesion, an effect mediated through a reduced recruitment of monocytes/macrophages into the vessel wall. 16 In addition to their function in the inflammatory response, CCR2 and CCR5 act as coreceptors for the HIV-1 virus. 17 Several mutations (polymorphisms) at the CCR2 and CCR5 genes have been described, being involved in the resistence to HIV-1 infection and the rate of AIDS progression. [18] [19] [20] [21] [22] [23] Thus, individuals who are homozygous for a 32-bp deletion at the CCR-5 gene (the ⌬ccr5 mutation) are almost completely resistant to HIV-1 infection, and ⌬ccr5 heterozygotes showed a slow progression towards AIDS compared to wild-type homozygotes. The ⌬ccr5 allele encodes a truncated protein that is not expressed on membrane cells, with ⌬ccr5/⌬ccr5 individuals having a complete lack of the receptor while ⌬ccr5 heterozygotes express lower amounts of the receptor compared to wild-type homozygotes. 24 A polymorphism at the CCR2 gene (V64I) has been described, and carriers of Isoleucine at codon 64 (the 64 I-allele) would be protected against HIV disease progression. 22, 23 The ⌬ccr5 and 64I alleles exist at a high frequency in most Caucasian populations. In this study we genotyped a number of patients with early (Ͻ55 years) and late (Ͼ60 years) myocardial infarction (MI), as well as healthy controls from the same Caucasian population. Our purpose was to determine whether the CCR5 and CCR2 polymorphisms contribute to the susceptibility to develop myocardial infarction or influences the age at the onset of the disease. Table 1 summarises the characteristics of patients and controls. All the individuals in both groups of patients were either smokers and/or hypertensives and/or had hypercholesterolaemia, three well recognised risk factors for coronary artery disease. Compared to controls, patients Ͻ55 years had a significantly higher frequency of smokers (P Ͻ 0.0001; OR = 23, 95% CI = 12.44, 44.70) and hypertensives (P Ͻ 0.0001; OR = 3.06, 95% CI = 2.01, 4.66). Average cholesterol and triglycerides values were higher in patients Ͻ55 years compared to controls, while the HDL-cholesterol value was lower in patients. However, these values were not significantly different between patients and controls. Table 2 summarises the CCR2 frequencies (V64I polymorphism) in patients and controls. The CCR2 allele and genotype frequencies did not differ between the three groups, suggesting that this polymorphism neither contributes to the risk of developing MI nor delays the outcome of coronary heart disease. Gene and genotype frequencies for the CCR5 polymorphism are summarised in Table 3 . We found a significantly lower frequency of the ⌬ccr5 allele among the youngest patients compared to controls (P = 0.004; OR = 0.42, 95% CI = 0.23-0.77) or to oldest patients (P = 0.002; OR = 0.42, 95% CI = 0.16, 0.68). No patient Ͻ55 years was ⌬ccr5-homozygote, compared to 1% among the controls. While 7% of the patients Ͻ55 years were ⌬ccr5-carriers (⌬/wt + ⌬/⌬), this frequency was 15% among the controls and 19% among the patients Ͼ60 years. These data suggest that non-carriers of the ⌬ccr5 allele have an early onset of the disease. Taking the patients Ͼ60 years as the reference group, wt/wt individuals would have a threefold higher risk of suffering an early episode (Ͻ55 years) of MI (OR = 3.06; 95% CI = 1.46-6.42).
Results
The CCR2 and CCR5 genes are closely linked on chromosome 3. We analysed if any genotype combination was more frequent in patients compared to controls. As summarised in Table 4 , CCR2/CCR5 genotype frequencies did not differ between the three groups.
Coronary angiograms were performed on 104 of the 
*Smokers, Ͻ55 years vs controls, P = 0.008; Ͻ55 vs Ͼ60, P = 0.007. **Hypertensives, Ͻ55 vs controls, P = 0.12; Ͻ55 vs Ͼ60, P = 0.03.
patients Ͻ55 years, and only three showed non-diseased vessels. Among the patients Ͼ60 years, a total of 36 were angiographically evaluated, and only two had nondiseased vessels. Gene and genotype frequencies for the CCR5 polymorphism did not differ between total patients and patients with angiographically confirmed diseased vessels. A similar result was obtained for the CCR2 polymorphism.
We also analysed the CCR5 genotypes distribution according to cardiovascular risk factors. As summarised in Table 5 , ⌬ccr5 carriers were at a similar frequency among hypertensives/normotensives, or smokers/nonsmokers. In addition, average lipid values did not differ between the different genotypes. When only smokers were compared, ⌬ccr5 carriers were at a higher frequency among patients Ͻ55 years compared to controls (P = 0.08) or to patients Ͼ60 years (P = 0.007).
Discussion
Our work suggests that carriers of the ⌬ccr5 mutation are at a lower frequency among patients with early MI, compared to controls and patients with a late-onset of the disease. These data support a role for this polymorphism modulating the age at the onset of the disease.
CCR5 and CCR2 are proinflammatory receptors that bind RANTES, MIP-1, and MCP-1. These chemokines are produced by the smooth muscle cells from the vascular endothelium, thus recruiting monocyte/macrophages to the vessel wall. This leukocyte contributes to the development of the arteriosclerotic lesion, a process that involves interactions between endothelial cells, vascular smooth muscle cells, macrophages and lymphocytes. 1, 2, 25 Monocytes/macrophages in the vessel wall accumulate lipids and become the foam cells (lipid-laden macrophages) that characterise the arterial fatty streak, which is the precursor of a more complex and dangerous lesion.
The importance of CCR2 in the initiation of atherosclerosis has been recently demonstrated by Boring et al. 16 These authors reported a decreased atherosclerotic lesion formation in mice (knock-out) lacking both apoE and CCR2, identifying CCR2 as a genetic determinant of murine arteriosclerosis. This effect could be mediated through a reduced leukocyte adhesion and monocyte extravasation in CCR2-null mice. 26, 27 In addition to CCR2, CCR5 has also been found in human aortic and coronary
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artery smooth muscle cells, and the MIP-1beta (a CCR5 ligand) was detected in smooth muscle cells and macrophages of the atherosclerotic plaque.
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CCR5 also acts as an HIV-1 coreceptor, and the ⌬ccr5 mutation has recently acquired particular relevance by confering resistance to HIV infection. [17] [18] [19] [20] [21] [22] [23] 28 The ⌬ccr5 allele encodes a truncated protein that does not reach the cell surface, with ⌬ccr5/⌬ccr5 homozygotes having a complete lack of the CCR5 on cells membrane, and ⌬ccr5 carriers expressing a reduced amount of the receptor compared to wild-type homozygotes. 24 Although they do not express CCR5, individuals homozygous for the ⌬ccr5 allele are healthy, probably due to the fact that the CCR5 ligands can exert their function by binding to other chemokine receptors. However, it is possible that the total or partial absence of CCR5 determines differencies in the rates of progression for diseases in which the inflammatory response is involved, particularly those in which RANTES and MIP-1 play a role. In this way, ⌬ccr5 carriers could have a reduced inflammatory response in vascular endothelium. As a consequence, the atherosclerotic lesion could develop at a slower rate in ⌬ccr5 carriers compared to wild-type homozygotes, who would suffer the MI at an earlier age.
A similar result has been found in asthma and in rheumatoid arthritis. These are diseases with an inflammatory component, and ⌬ccr5 carriers would be protected against the disease, or would develop a less severe form of the disease, compared to CCR5 wild-type homozygotes. [29] [30] [31] [32] The V64I polymorphism at the CCR2 gene has also been associated with differencies in HIV disease progression, with the 64I-allele having a protective role. 22 It is unlikely that the presence of valine or isolecine determines major functional changes in CCR2, and the different biological properties of this polymorphism could be a consequence of a linkage disequilibrium with a different polymorphism at the CCR2 and/or CCR5 genes, closely linked on chromosome 3. Because the CCR2-gene and genotype frequencies were similar in MI patients and healthy controls, this polymorphism would not contribute to the susceptibility to develop the disease. In addition, our data do not support a role for the CCR2-polymorphism in modulating the onset of MI.
Some previous reports have analysed the genetic variation at several inflammatory molecules in coronary artery disease. 33 To our knowledge, our work represents the first attempt to define a role for polymorphisms at the proinflammatory receptors in MI. Apart from CCR2 and CCR5, other chemokine receptors are actively expressed on monocytes, and polymorphisms at these genes could contribute to the susceptibility to develop MI, or determine differencies in the rate of disease progression. Our work has several limitations. First of all, data from case-control studies are subjected to a number of possible confounding factors, the total number of patients and controls and the homogeneity of the population (in terms of sex, geographical origin, and age) among others. Although based on a reduced number of patients, our study included only males from the same region. In addition, the CCR5 and CCR2-polymorphisms were in the Hardy-Weinberg equilibrium in our population, suggesting the absence of population biases. The role of the CCR5 polymorphism in modulating the origin of the atherosclerotic plaque cannot be established from our work. This would require us to genotype a group of oldhealthy controls with MI risk factors and without diseased vessels. However, coronariographic analysis is expensive and potentially dangerous, and was only performed in the patients as a diagnostic tool.
Finally, the role of CCR5 (and other proinflammatory receptors) in HIV infection and AIDS development has made the development of drugs that target these receptors a major goal of research. Homozygotes for the ⌬ccr5 mutation are a natural knock-out for the CCR5 gene. These individuals are healthy, and the specific pharmacological targeting of CCR5 in order to abolish its function would not have undesirable symptoms. If works on other populations confirm the role of the genetic variation at the CCR5 in modulating the onset of MI, anti-CCR5 drugs could be a valuable therapy in the treatment of this disease.
Methods

Patients and controls
This work was designed to analyse the influence of the CCR2 and CCR5 polymorphisms in the risk for MI or in the age at the onset of MI. A total of 310 consecutive male patients younger than 55 years or older than 60 years were analysed. These patients attended our Cardiology Department between January 1996 and December 1999, by suffering a first episode of MI defined according to the WHO criteria. A total of 214 and 96 patients were younger than 55 years and older than 60 years, respectively. We also analysed 360 male healthy controls (blood donors, hospital staff, eligible residents). These controls had not suffered episodes of cardiovascular disease. Patients and controls were Caucasians from the same region (Asturias, northern Spain, total population 1 million). Each participant gave informed consent for the study, which was approved by the Ethics Committee of Hospital Central Asturias. Coronary angiograms were performed on 49% of the youngest patients (104/214), and on 38% of the oldest patients (36/96). According to the angiographic appearance, a vessel was regarded as diseased if it contained at least one stenosis involving Ͼ30% loss of lumen diameter.
Individuals with a blood systolic pressure Ͼ150 mm Hg in more than one determination were defined as hypertensives. A smoking history from all subjects was obtained, and a lipid profile in blood that included total cholesterol, triglycerides, and HDL-cholesterol was also determined for each patient and control. Hypercholesteroloemia was defined as a total cholesterol Ͼ250 mg/dl.
Genotyping of the CCR5 and CCR2 polymorphisms
Genomic DNA was obtained from patients and controls. For the analysis of the ⌬ccr5-allele, genomic DNA was PCR-amplyfied in a final volume of 30 l containing 30 pmol of each primer (forward -CTGTGTTTGCG TCTCTCCCA and reverse-CCTCTTCTTCTCATTTCGA-CAC CG), 2 mm of each dNTP, 2 mm MgCl 2 , 1 × Taq polymerase buffer, and 0.5 U of Taq DNA polymerase. After 32 cycles of 95°C for 20 s, 62°C for 1 min and 72°C for 30 s, 15 l of the reaction was electrophoresed on a 3% agarose gel and alleles visualised, after ethidium bromide staining, as fragments of 222 bp (wild-type allele) and 190 bp (⌬ccr5-allele).
For the analysis of the G/A polymorphism at codon 64 (Val/Ile) of the CCR2 gene a 215 bp sequence was amplified with primers fwd.-ATGCTGTCCACATC TCGTTCT and rvs.-TTTTTGCAGTTTATTAAGATGA GT. PCR conditions were as described for the CCR5 sequence, with an annealing temperature of 62°C. Ten l of each reaction were digested with 10 U of the restriction enzyme RsaI, and electrophoresed on a 4% agarose gel. Alleles were visualised as fragments of 191 bp (64V) and 215 bp (64I).
Statistical analysis
The chi-square test was used to compare gene and genotype frequencies between the groups. Odds Ratios (OR's) and their 95% confidence interval (CI) were also calculated. A P Ͻ 0.05 indicated a statistically significant difference. Average biochemical values were compared between the genotypes through an ANOVA test. The statistitical analysis was performed with the computer programm BMDP-New Systems (BMDP statistical software, Cork, Ireland).
